April 28, 2026 —
Rocket Pharmaceuticals has sold its FDA rare pediatric disease priority review voucher (PRV) for $180 million, underscoring sustained demand for accelerated regulatory pathways and the growing financial value tied to successful gene therapy approvals.
The voucher was awarded following the FDA’s accelerated approval of Kresladi, a hematopoietic stem cell-based gene therapy for Leukocyte Adhesion Deficiency Type 1, a rare and life-threatening pediatric immune disorder.
PRVs allow companies to shorten FDA review timelines for future therapies—from the standard 10 months to approximately six months—or to monetize the asset through sale to other developers. In this case, Rocket opted to sell the voucher to an undisclosed buyer, using the proceeds to extend its financial runway into Q2 2028 and support advancement of its cardiovascular gene therapy pipeline.
The transaction reflects a broader trend in the PRV market, where voucher values have climbed significantly in recent years. Historically priced near $100 million, recent deals have consistently exceeded that level, including transactions by Bavarian Nordic, Zevra Therapeutics, and Jazz Pharmaceuticals, with some reaching the $200 million range.
Rocket’s $180 million sale suggests the market remains strong, even as pricing appears to be stabilizing slightly below recent peak levels.
The renewed strength of the PRV ecosystem also follows legislative action. The program, originally established in 2012, was recently reauthorized through September 2029 after a period of uncertainty, reinforcing its role as a key incentive for rare disease drug development. Policymakers, including FDA leadership, have even proposed making the program permanent.
At the same time, the regulatory landscape continues to evolve. The FDA has introduced a separate initiative—the Commissioner’s National Priority Voucher (CNPV) program—designed to accelerate reviews even further for therapies aligned with national health priorities. Unlike traditional PRVs, however, these vouchers are non-transferable.
Notably, the first gene therapy approved under this newer framework was Otarmeni from Regeneron Pharmaceuticals, highlighting how regulatory innovation is increasingly intersecting with advances in genetic medicine.
For companies like Rocket, the ability to convert regulatory incentives into capital remains strategically important—particularly in a market where funding efficiency and pipeline prioritization are under close scrutiny.
